Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Close vs Range

Score

-0.65

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 87 5.6 0.37% 0.57% 7.3% -3.4% 40.3%
SHORT 85 4.8 0.33% 0.44% 3.5% -3.6% -132.0%

Summary

Technical Analysis


Where the closing price fall within the day’s trading range highlights whether are in control.

[Calculations] Close Today Versus Range Today (CTRT):
1) When the closing price is near the high of the day buyers were in control at the close of the trading session;
2) When the closing price is near the low of the day sellers were in control at the close of the trading session;
3) When the closing price is near the middle of the day’s range where neither the buyers or sellers were in control at the close of the trading session;


PROFILE: Ra Pharmaceuticals Inc (RARX)


Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

Close vs Range

Download
Company Close Change(%) Volume Value Signal
INO Inovio Pharma 4.36 9.3 34,675,337 -1 BEARISH
FOSL Fossil Group 4.28 2.6 1,864,683 -1 BEARISH
NH Nanthealth 1.8 1.7 455,155 -1 BEARISH
CETV Central European Media 4.4 0.9 2,014,369 -1 BEARISH
CSWI CSW Industrials 70.37 0.4 93,298 -1 BEARISH
HIFS Hingham Institution for Savings 186.5 0 8,469 -1 BEARISH
AXGN Axogen 12.98 -0.1 418,801 -1 BEARISH
GPP Green Plains Partners 13.56 -0.3 115,848 -1 BEARISH
MAT Mattel Inc 11.53 -1 8,367,251 -1 BEARISH
GT Goodyear Tire Rubber 9.91 -1.1 6,649,543 -1 BEARISH